PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-20.40%
Both yoy net incomes decline, with AXSM at -9.09%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
5.37%
D&A growth well above AXSM's 3.71%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
42.67%
Deferred tax of 42.67% while AXSM is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-15.52%
Negative yoy SBC while AXSM is 52.65%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
2.45%
Less working capital growth vs. AXSM's 241.91%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.66%
Negative yoy AP while AXSM is 208.78%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
389.89%
Growth well above AXSM's 85.31%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-15.52%
Negative yoy while AXSM is 67.77%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-26.74%
Negative yoy CFO while AXSM is 8.04%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
51.76%
CapEx growth well above AXSM's 52.12%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy purchasing while AXSM stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
No Data
No Data available this quarter, please select a different quarter.
169.66%
Growth well above AXSM's 100.00%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
253.33%
Investing outflow well above AXSM's 52.12%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
100.00%
Debt repayment growth of 100.00% while AXSM is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-79.28%
Negative yoy issuance while AXSM is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.